Bacopa Monnieri Extract 10%-50% Bacopaside Purslane Leaf Extract

Name: Bacopa Monnieri Extract 10%-50% Bacopaside Purslane Leaf Extract
Brand: Xi'an Xinlu Biotechnology Co., Ltd.
SKU: 2171675015

Shaanxi, ChinaXi'an Xinlu Biotechnology Co., Ltd.

US$13.00-25.00

1 kg

Sample price:US$25.00/kg.Request sample

Product profile

Customization

Available

Certification

ISO

Assay Method

HPLC

Model NO.

PLANT

Application Form

Tablet, Capsule

Application

Food, Health Care Products

State

Powder

Extract Source

Purslane Leaf Extract

Keyword

Bacopaside

Sample

Available

MOQ

Consult

CAS

93164-89-7

Test Method

HPLC

Transport Package

Aluminum Foil Bag/Paper Drum

Specification

10-50%

Trademark

xinlu

Origin

China

Production Capacity

100kg

Company profile

In-stock CapacityFast DeliveryOEM ServicesR&D Capabilities

Xi'an Xinlu Biotechnology Co., Ltd.

Shaanxi, China

Business Type: Manufacturer/Factory CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 5 years CertifiedNearest Port: Shanghai PortAverage Response Time: ≤1.61h

AI-Powered supplier vetting

SummaryXi'an Xinlu Biotechnology Co., Ltd. was established in 2015 and specializes in the R&D, production, processing, and sales of natural plant extracts and pharmaceutical intermediates. Its stated product range includes Matrine, Oxymatrine, Magnolol, Honokiol, Gentiopicroside, Cytisine, and other compounds. The supplier reports OEM service for well-known brands, in-stock capability, broad customization options, and export activity accounting for 51%–70% of total sales. However, it reports no available SDK, no overseas warehouse, showroom, agents, branches, or offline trade-show participation. Quality-system evidence is weak: there are no written corrective-action or complaint-handling procedures, and quality-control testing equipment is reported as zero. Certification, raw-material traceability, environmental documentation, fire-drill practices, and manufacturing-contract status remain unverified.

Supplier typeThe supplier is a biotechnology company focused on the R&D, production, processing, and sales of natural plant extracts and pharmaceutical intermediates. Its permitted business scope also includes pre-packaged food, non-food health products, and import/export activities, indicating a manufacturer and trading-capable supplier rather than a purely service-based company.

After-Sales capabilityThe supplier reports in-stock service capability and accepts FOB, CIF, CFR, and EXW quotation terms. Nevertheless, it has no overseas warehouse, showroom, agents, or branches, and reports no written procedures or records for customer complaint handling or corrective and preventive actions, which is a stated service-process deficiency.

R&D capabilityThe supplier describes itself as having R&D capability, offers customized product development, and can cooperate with customers to develop new products. However, it explicitly reports no available SDK, so software-development integration capability is absent; overall innovation strength is only partially evidenced.

Production capacityThe supplier describes production and processing capabilities, lists multiple plant-derived compounds, operates from a site of about 10,000 square meters, and reports inventory capability. However, manufacturing-contract status is unknown and the quality-control section reports zero testing equipment, creating a material concern about documented production-control capability.

Customization capabilityThe supplier explicitly supports customization from samples, designs, full customization, minor customization, and flexible customization. It also states that it can produce according to customer needs and cooperate in developing new products, providing direct evidence of broad customization capability.